Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk

References

• CariouBCharbonnelBStaelsBThiazolidinediones and PPARγ agonists: time for a reassessmentTrends Endocrinol Metab201223520521522513163
   PubMed Web of Science ®Google Scholar
• KungJHenryRRThiazolidinedione safetyExpert Opin Drug Saf201211456557922616948
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialLancet200937396812125213519501900
   PubMed Web of Science ®Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsJAMA2007298101180118817848652
   PubMed Web of Science ®Google Scholar
• WatkinsPBWhitcombRWHepatic dysfunction associated with troglitazoneN Engl J Med1998338139169179518284
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• LagoRMSinghP PNestoRWCongestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trialsLancet200737095931129113617905165
   PubMed Web of Science ®Google Scholar
• DorkhanMDenckerMStagmoMGroopLEffect of pioglitazone versus insulin glargine on cardiac size, function and measures of fluid retention in patients with type 2 diabetesCardiovasc Diabetol20098152019298680
   PubMed Web of Science ®Google Scholar
• SinghSLokeYFurbergCLong-term risk of cardiovascular events with rosiglitazone: a meta-analysisJAMA2007298101189119517848653
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJASecondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trialLancet200536694931279128916214598
   PubMed Web of Science ®Google Scholar
• FanarowGCApproach to the management of diabetic patients with heart failure: role of thiazolidinedionesAm Heart J2004148455155815459582
   PubMed Web of Science ®Google Scholar
• MasoudiFAInzucchiSEWangYHavranekE PFoodyJMKrumholzHMThiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. An observational studyCirculation2005111558359015699279
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRonnemaaTPyoralaKLaaksoMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med199833942292349673301
   PubMed Web of Science ®Google Scholar
• BrenerSJLytleB WCasserlyI PTopolEJLauerMSPropensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary disease and high-risk featuresCirculation2004109192290229515117846
   PubMed Web of Science ®Google Scholar
• ScholteAJSchuijfJDKharagjitsinghAVPrevalence of coronary artery disease and plaque morphology assessed by multi-slice computed tomography coronary angiography and calcium scoring in asymptomatic patients with type 2 diabetesHeart200894329029517646190
   PubMed Web of Science ®Google Scholar
• WallerBFPalumboPJLieJTRobertsWCStatus of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years: analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjectsAm J Med19806944985067424939
   PubMed Web of Science ®Google Scholar
• GuKCowieCCHarrisMIDiabetes and decline in heart disease mortality in US adultsJAMA1999281141291129710208144
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA2008299131561157318378631
   PubMed Web of Science ®Google Scholar
• KuusistoJMykkänenLPyöräläKLaaksoMHyperinsulinemic microalbuminuria: a new risk indicator for coronary heart diseaseCirculation19959138318377828312
   PubMed Web of Science ®Google Scholar
• EastmanRCKeenHThe impact of cardiovascular disease on people with diabetes: the potential for preventionLancet1997350Suppl 1SI29SI329250281
   PubMedGoogle Scholar
• MattockMBMorrishNJVibertiGKeenHFitzgeraldA PJacksonGProspective study of microalbuminuria as predictor of mortality in NIDDMDiabetes19924167367411587400
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHMatthewsDRCharbonnelBHOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427114114714693980
   PubMed Web of Science ®Google Scholar
• AgrawalBWolfKBergerALuftFCEffect of antihypertensive treatment on qualitative estimates of microalbuminuriaJ Hum Hypertens19961085515558895040
   PubMed Web of Science ®Google Scholar
• NakamuraTUshiyamaCOsadaSHaraMShimadaNKoideHPioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuriaMetabolism200150101193119611586492
   PubMed Web of Science ®Google Scholar
• KoskinenPManttariMManninenVHuttunenJKHeinonenO PFrickMHCoronary heart disease incidence in NIDDM patients in the Helsinki Heart StudyDiabetes Care19921578208251516498
   PubMed Web of Science ®Google Scholar
• HaffnerSMDyslipidemia management in adults with diabetesDiabetes Care200427Suppl 1S68S7114693930
   PubMedGoogle Scholar
• GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052871547155415983299
   PubMed Web of Science ®Google Scholar
• BerhanuPKipnesMSKhanMAEffects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapyDiab Vasc Dis Res200631394416784180
   PubMedGoogle Scholar
• DavidsonMMeyerPMHaffnerSIncreased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitusCirculation2008117162123213018413496
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFD’AngeloAEffects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, doubleblind, controlled clinical trialClin Ther200628567968816861090
   PubMed Web of Science ®Google Scholar
• HanefeldMMarxNPfütznerAAnti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT StudyJ Am Coll Cardiol200749329029717239709
   PubMed Web of Science ®Google Scholar
• KaragiannisEPfütznerAForstTThe IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditionsDiabetes Technol Ther200810320621218473695
   PubMed Web of Science ®Google Scholar
• ForstTKaragiannisELübbenGPleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery diseaseAtherosclerosis2008197131131717588584
   PubMed Web of Science ®Google Scholar
• HondaTKaikitaKTsujitaKPioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disordersJ Mol Cell Cardiol200844591592618436235
   PubMed Web of Science ®Google Scholar
• LiJLangMJMaoXBTianLFengYBAntiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of ratCardiovasc Drugs Ther200822428329118470603
   PubMed Web of Science ®Google Scholar
• YeYLinYManickavasagamSPerez-PoloJRTieuBCBirnbaumYPioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout miceAm J Physiol Heart Circ Physiol20082956H2436H244618931027
   PubMed Web of Science ®Google Scholar
• WangHZhuQ WYePPioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2Biosci Trends20126632533223337792
   PubMed Web of Science ®Google Scholar
• MeierCKraenzlinMEBodmerMJickSSJickHMeierCRUse of thiazolidinediones and fracture riskArch Intern Med2008168882082518443256
   PubMed Web of Science ®Google Scholar